DukeSpace will be down for maintenance at 9:15 AM EDT on Tuesday, July 29. Expected downtime is 20 minutes or less.

Show simple item record

dc.contributor.author Grabowski, Henry en_US
dc.contributor.author Vernon, John en_US
dc.date.accessioned 2010-06-28T19:00:30Z
dc.date.available 2010-06-28T19:00:30Z
dc.date.issued 1990-07 en_US
dc.identifier.uri http://hdl.handle.net/10161/2605
dc.description.abstract This study investigates the returns to R&D for 100 new drugs introduced into the United States during the decade of the 1970s. In contrast to prior studies, it incorporates several significant structural changes that have occurred in the pharmaceutical industry during the 1980s. These include higher real drug prices and a greater degree of generic competition. A major finding is that the return on R&D for the average new drug is approximately equal to the 9 percent industry cost of capital. However, the performance of new drugs introduced during the latter half of the 1970s was markedly better than that of early 1970s introductions. This latter finding is consistent with the more rapid rate of industry growth in real R&D expenditures. The study also finds that the variation in returns is highly skewed, with only the top 30 drugs covering mean R&D costs on a fully allocated basis. Finally, it is shown that real drug price increases in the 1980s were necessary for the average new drug introduction to recover its R&D costs. en_US
dc.format.extent 472428 bytes
dc.format.mimetype application/pdf
dc.language.iso en_US
dc.publisher Management Science en_US
dc.subject Pharmaceutical R&D en_US
dc.subject Returns and Risks en_US
dc.title A New Look at the Returns and Risks to Pharmaceutical R&D en_US
dc.type Journal Article en_US
dc.department Economics

Files in this item

This item appears in the following Collection(s)

Show simple item record